Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value
Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...
754 Views
Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium
Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing. In this note,...
511 Views
Jiangsu Hengrui Pharma A/H Listing - Recent Updates and Thoughts on A/H Premium
The company has now filed its PHIP and is said to be pre-marketing with an aim to launch the deal in the coming week. Although it would have to...
809 Views
Hong Kong Connect Flows (April): US$22bn Inflows
We analyzed the Hong Kong Connect Scheme for April and highlighted flows for Alibaba, TraHK HSI ETF, Tencent, Meituan, HSCEI ETF.
339 Views
A/H Premiums and past A/H Listings Performance Data - Mixed Results but Size Matters
Given the slew of A/H offerings in the Hong Kong IPO pipeline, in this note, we talk about the overall A/H premiums currently.
785 Views